Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD)

Medicine and Dentistry

• Atherosclerosis 11%
• Attention 11%
• Calcification 100%
• Cardiovascular System 88%
• Cholesterol 11%
• Combination Therapy 11%
• Coronary Artery Calcification 44%
• Dyslipidemia 22%
• End Stage Renal Disease 66%
• Etiology 11%
• Inpatient 55%
• Isotopes of Calcium 44%
• Kidney Function 11%
• Low Density Lipoprotein Cholesterol 44%
• Marker 11%
• Pathogenesis 22%
• Patient 22%
• Phosphate Binder 22%
• Plasma 11%
• Population 11%
• Risk Factor for Atherosclerosis 11%
• Sevelamer 33%
• Statin 11%
• Therapeutic Procedure 22%
• Thinking 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Atherosclerosis 11%
• Calcification 100%
• Calcium 44%
• Cholesterol 11%
• Clinical Study 33%
• Coronary Artery Calcification 44%
• Dialysis 11%
• Dyslipidemia 22%
• End Stage Renal Disease 66%
• Etiology 11%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 22%
• Low Density Lipoprotein Cholesterol 44%
• Pathogenesis 22%
• Phosphate Binding Agent 22%
• Sevelamer 33%
• Statin (Protein) 11%

Biochemistry, Genetics and Molecular Biology

• Attention 11%
• Calcium 44%
• Cholesterol 22%
• Cholesterol Blood Level 11%
• Contrast 11%
• Dialysis 11%
• Dyslipidemia 22%
• Electric Potential 11%
• Kidney Function 11%
• Low Density Lipoprotein Cholesterol Level 22%
• Phosphate 22%
• Population 11%
• Reduction (Chemistry) 11%
• Statin 11%
• thought 11%